- Home
- RCKT vs LBRX Comparison
RCKT vs LBRX Comparison
Compare RCKT & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCKT
- LBRX
- Stock Information
- Founded
- RCKT 1999
- LBRX 2015
- Country
- RCKT United States
- LBRX United States
- Employees
- RCKT N/A
- LBRX N/A
- Industry
- RCKT Biotechnology: Pharmaceutical Preparations
- LBRX Biotechnology: Pharmaceutical Preparations
- Sector
- RCKT Health Care
- LBRX Health Care
- Exchange
- RCKT Nasdaq
- LBRX Nasdaq
- Market Cap
- RCKT 328.6M
- LBRX 337.7M
- IPO Year
- RCKT N/A
- LBRX 2025
- Fundamental
- Price
- RCKT $3.17
- LBRX $15.77
- Analyst Decision
- RCKT Buy
- LBRX Strong Buy
- Analyst Count
- RCKT 13
- LBRX 3
- Target Price
- RCKT $12.88
- LBRX $46.33
- AVG Volume (30 Days)
- RCKT 2.3M
- LBRX 421.5K
- Earning Date
- RCKT 11-06-2025
- LBRX 01-01-0001
- Dividend Yield
- RCKT N/A
- LBRX N/A
- EPS Growth
- RCKT N/A
- LBRX N/A
- EPS
- RCKT N/A
- LBRX N/A
- Revenue
- RCKT N/A
- LBRX N/A
- Revenue This Year
- RCKT N/A
- LBRX N/A
- Revenue Next Year
- RCKT $108.43
- LBRX N/A
- P/E Ratio
- RCKT N/A
- LBRX N/A
- Revenue Growth
- RCKT N/A
- LBRX N/A
- 52 Week Low
- RCKT $2.19
- LBRX $13.36
- 52 Week High
- RCKT $18.89
- LBRX $20.25
- Technical
- Relative Strength Index (RSI)
- RCKT 48.26
- LBRX N/A
- Support Level
- RCKT $3.13
- LBRX N/A
- Resistance Level
- RCKT $3.44
- LBRX N/A
- Average True Range (ATR)
- RCKT 0.17
- LBRX 0.00
- MACD
- RCKT -0.01
- LBRX 0.00
- Stochastic Oscillator
- RCKT 35.11
- LBRX 0.00
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.